Cargando…

Human-specific dual regulations of FXR-activation for reduction of fatty liver using in vitro cell culture model

Nuclear receptor farnesoid X receptor activation inhibits fatty acid synthesis through the liver X receptor-α-sterol regulatory element binding protein-1c pathway universally in animals, but also has human-specific crosstalk with the peroxisome proliferator-activated receptor-α. The effects of farne...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miyazaki, Teruo, Honda, Akira, Ikegami, Tadashi, Iida, Takashi, Matsuzaki, Yasushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	the Society for Free Radical Research Japan 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436045/ https://www.ncbi.nlm.nih.gov/pubmed/30936623 http://dx.doi.org/10.3164/jcbn.18-80

Ejemplares similares

Upregulation of Taurine Biosynthesis and Bile Acid Conjugation with Taurine through FXR in a Mouse Model with Human-like Bile Acid Composition
por: Miyazaki, Teruo, et al.
Publicado: (2023)

Simultaneous quantification of salivary 3-hydroxybutyrate, 3-hydroxyisobutyrate, 3-hydroxy-3-methylbutyrate, and 2-hydroxybutyrate as possible markers of amino acid and fatty acid catabolic pathways by LC–ESI–MS/MS
por: Miyazaki, Teruo, et al.
Publicado: (2015)

Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment
por: Hirayama, Takeshi, et al.
Publicado: (2017)

Serum carnitine as an independent biomarker of malnutrition in patients with impaired oral intake
por: Iwamoto, Junichi, et al.
Publicado: (2014)

Fatty liver diseases, bile acids, and FXR
por: Zhu, Yan, et al.
Publicado: (2016)

Determination of Key Intermediates in Cholesterol and Bile Acid Biosynthesis by Stable Isotope Dilution Mass Spectrometry
por: Yoshida, Tadashi, et al.
Publicado: (2008)

Development and in vitro Profiling of Dual FXR/LTA4H Modulators
por: Schierle, Simone, et al.
Publicado: (2021)

Western Diet Changes Gut Microbiota and Ameliorates Liver Injury in a Mouse Model with Human‐Like Bile Acid Composition
por: Iwamoto, Junichi, et al.
Publicado: (2021)

Liver Capsule: FXR agonists against liver disease
por: Fuchs, Claudia D., et al.
Publicado: (2016)

The Effects of PPAR Agonists on Atherosclerosis and Nonalcoholic Fatty Liver Disease in ApoE(−/−)FXR(−/−) Mice
por: Lee, Yenna, et al.
Publicado: (2021)

Bioenergetic cues shift FXR splicing towards FXRα2 to modulate hepatic lipolysis and fatty acid metabolism
por: Correia, Jorge C., et al.
Publicado: (2015)

Evaluation of the Risk of Clostridium difficile Infection Using a Serum Bile Acid Profile
por: Monma, Tadakuni, et al.
Publicado: (2022)

Sex-, age-, and organ-dependent improvement of bile acid hydrophobicity by ursodeoxycholic acid treatment: A study using a mouse model with human-like bile acid composition
por: Ueda, Hajime, et al.
Publicado: (2022)

The ameliorating effect of withaferin A on high-fat diet-induced non-alcoholic fatty liver disease by acting as an LXR/FXR dual receptor activator
por: Shiragannavar, Varsha D., et al.
Publicado: (2023)

Selective targeting of nuclear receptor FXR by avermectin analogues with therapeutic effects on nonalcoholic fatty liver disease
por: Jin, Lihua, et al.
Publicado: (2015)

Effects of cholesterol-lowering probiotics on non-alcoholic fatty liver disease in FXR gene knockout mice
por: Yang, Minghua, et al.
Publicado: (2023)

Dual Activation of the Bile Acid Nuclear Receptor FXR and G-Protein-Coupled Receptor TGR5 Protects Mice against Atherosclerosis
por: Miyazaki-Anzai, Shinobu, et al.
Publicado: (2014)

Bile Acids and FXR: Novel Targets for Liver Diseases
por: Stofan, Mary, et al.
Publicado: (2020)

Concurrent miR-21 suppression and FXR activation as a mechanism of improvement in nonalcoholic fatty liver disease
por: Mazzini, Guilherme S., et al.
Publicado: (2018)

SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis
por: Zhou, Jiyu, et al.
Publicado: (2020)

Impaired bile acid metabolism with defectives of mitochondrial-tRNA taurine modification and bile acid taurine conjugation in the taurine depleted cats
por: Miyazaki, Teruo, et al.
Publicado: (2020)

FXR Controls the Tumor Suppressor NDRG2 and FXR Agonists Reduce Liver Tumor Growth and Metastasis in an Orthotopic Mouse Xenograft Model
por: Deuschle, Ulrich, et al.
Publicado: (2012)

FXR and NASH: an avenue for tissue-specific regulation
por: Henry, Zakiyah, et al.
Publicado: (2023)

Discovery, optimization, and evaluation of non-bile acid FXR/TGR5 dual agonists
por: Miyata, Sachiho, et al.
Publicado: (2021)

Farnesoid X Receptor (FXR) Activation and FXR Genetic Variation in Inflammatory Bowel Disease
por: Nijmeijer, Rian M., et al.
Publicado: (2011)

The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease
por: Zhang, Dan-Ying, et al.
Publicado: (2019)

Effects of Poria cocos extract on metabolic dysfunction-associated fatty liver disease via the FXR/PPARα-SREBPs pathway
por: He, Jinbiao, et al.
Publicado: (2022)

Ablation of liver Fxr results in an increased colonic mucus barrier in mice
por: Ijssennagger, Noortje, et al.
Publicado: (2021)

Evaluation of gut dysbiosis using serum and fecal bile acid profiles
por: Monma, Tadakuni, et al.
Publicado: (2022)

Effects of the Concomitant Use of Low-dose Clarithromycin with an Anti-TNFα Antibody in a Patient with Intestinal Behçet Disease
por: Iwamoto, Junichi, et al.
Publicado: (2017)

Reconstruction of FXR Beam Conditions
por: Nexsen, W E, et al.
Publicado: (2001)

BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis
por: Carino, Adriana, et al.
Publicado: (2017)

Population‐based meta‐analysis and gene‐set enrichment identifies FXR/RXR pathway as common to fatty liver disease and serum lipids
por: Handelman, Samuel K., et al.
Publicado: (2022)

Corrigendum: Effects of Poria cocos extract on metabolic dysfunction-associated fatty liver disease via the FXR/PPARα-SREBPs pathway
por: He, Jinbiao, et al.
Publicado: (2023)

Elastography Techniques for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease
por: Honda, Yasushi, et al.
Publicado: (2020)

FXR1 promotes proliferation, invasion and migration of hepatocellular carcinoma in vitro and in vivo
por: Zhao, Kun, et al.
Publicado: (2022)

Nuclear receptors FXR and SHP regulate protein N-glycan modifications in the liver
por: Mathur, Bhoomika, et al.
Publicado: (2021)

SIRT1 activation synergizes with FXR agonism in hepatoprotection via governing nucleocytoplasmic shuttling and degradation of FXR
por: Cui, Shuang, et al.
Publicado: (2023)

Novel FXR agonist nelumal A suppresses colitis and inflammation-related colorectal carcinogenesis
por: Miyazaki, Tsuneyuki, et al.
Publicado: (2021)

FXR controls CHOP expression in steatohepatitis
por: Fuchs, Claudia D., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_88siv66jbvtg9kj50c4b14bvhu